Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE-MASH: TGM-312-SC01 in Healthy Participants and Adults With MASH
NCT07427680Phase 2Recruiting
- Sponsor
- Tangram Therapeutics
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of TGM-312 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Tangram Therapeutics. Started Mar 2026; status: recruiting.
02
Drugs
TGM-312
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07427680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07427680.